News

Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that it has entered into a royalty purchase agreement with an entity that was provided capital by funds managed by Blue Owl Capital Inc. (“Blue Owl”) (the “Agreement”), dated March 31, 2025, to sell the royalty interest in annual net sales of BENDEKA® (bendamustine hydrochloride injection) in the United States for an aggregate purchase price of $69 million before transaction costs.

Nuvation Bio to receive $150 million in royalty interest financing and $50 million in debt upon U.S. FDA approval of taletrectinib, with access to additional $50 million in debt at the Company’s option

We are excited to announce that our team will be attending the event and is interested in discussing RM opportunities.

In today's challenging fundraising environment for biotech and pharma companies innovative financing mechanisms are essential. Ligand Pharmaceuticals's recent $75 million royalty financing to further Castle Creek Biosciences Phase 3 clinical asset in DEB offers a compelling non-dilutive financing alternative. This deal creates a synthetic royalty on future revenue streams, unlocking value without diluting equity. Notably, the syndication of risk among multiple investors including XOMA Royalty, which is not commonly seen, further spreads risk and opens additional avenues for funding new therapies. Unlock the future of biotech financing—reach out to explore how royalty solutions can bridge your financing needs.

Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that it has entered into a royalty purchase agreement with Soleus Capital Credit Opportunities Fund I, L.P. (and any affiliated entity "Soleus"), an investment fund managed by Soleus Capital Management, L.P. ("Soleus Capital"), a US-based life sciences investment firm.

For Partnering & Investment at Hilton Zurich Airport Hotel.